

Next Science Group
Level 19, Tower A, The Zenith
821 Pacific Highway, Chatswood
NSW 2067
Australia

Next Science and 3M enter exclusive distribution agreement for BlastX™ Wound Gel

Sydney, NSW: Australian biotechnology firm Next Science today announced that it had entered into an exclusive, worldwide distribution agreement with US-based diversified manufacturer 3M Company for the sales and marketing of Next Science's BlastX™ Antimicrobial Wound Gel.

BlastX™ Wound Gel is powered by Next Science's patented Xbio™ Technology that dramatically improves clinical outcomes for patients suffering from chronic wounds.

Under the agreement, 3M will begin exclusive distribution of BlastX™ Wound Gel from 1 January 2019, initially in the US and then globally as regulatory approvals are secured in Europe, Canada, Australia, Japan and other markets.

Next Science CEO, Judith Mitchell, said "the 3M agreement is validation of Next Science's proprietary Xbio™ Technology and we look forward to the growth potential of BlastX™ Wound Gel in the US and globally."

"Next Science takes pride in the science underpinning our products and the effect they can have on people under medical care. We actively seek partners for our products that helps us reach the greatest number of people in need. With access to 3M's powerful global footprint we can now expect to reach millions of patients around the world suffering from chronic wounds more quickly than we would have otherwise," Ms Mitchell said.

BlastX™ Wound Gel applies an innovative material science approach that first deconstructs the bacterial biofilm matrix (EPS) — a major barrier to healing — before destroying harmful bacteria within the gel and defending the wound from recolonization, while maintaining a moist wound environment. The gel is currently sold in the US to customers, including Commercial Health Systems and the Federal Departments of Veteran's Affairs and Defense.

For more information on BlastX Wound Gel, click [here](#).

ENDS

NEXT SCIENCE®

***Note:** A specific communication will be emailed to all Next Science Customers with details of the transition plan. Both parties will endeavor to ensure minimal disruption to supply as we transition from Next Science supply to 3M supply.

About the Next Science Group

Next Science is an Australian Biotech company with headquarters in Sydney and its R&D and Operations centre in Jacksonville, Florida. Next Science pioneers innovative, proprietary material science technologies, including Xbio™ Technology, to address the problem of bacterial biofilms and already has a number of products on sale in the US. With proven, experienced management and scientific leadership, Next Science and its partners deliver break-through solutions that see beyond the current limits imposed by powerful bacterial colonies. Learn more at www.nextscience.com

About BlastX™ Antimicrobial Wound Gel

BlastX™ Wound Gel is a breakthrough antimicrobial wound gel powered by Next Science's patented, non-toxic, biofilm-disruption Xbio™ Technology. It deconstructs the bacterial biofilm EPS matrix, destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment. For more information on BlastX Wound Gel, click [here](#).
Currently for sale in the US only.

Partnering Inquiries – Next Science:

Byron Darroch

Executive VP, Global

+61 2 8607 5124

bdarroch@nextscience.com

Client Inquiries USA – Next Science:

Don Ayers

VP, Sales & Marketing

sales@nextscience.com